Prostaglandin E2 couples through EP4 prostanoid receptors to induce IL‐8 production in human colonic epithelial cell lines
Open Access
- 17 February 2009
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 156 (3) , 475-485
- https://doi.org/10.1111/j.1476-5381.2008.00056.x
Abstract
Background and purpose: Prostaglandin (PG) E2 and interleukin (IL)-8 are simultaneously increased during the inflammation that characterizes numerous pathologies such as inflammatory bowel disease. IL-8 is a potent neutrophil chemo-attractant and activator, and can initiate and/or exacerbate tissue injury. PGE2 signals principally through prostanoid receptors of the EP2 and/or EP4 subtypes to promote cAMP-dependent cellular functions. The aim of this study was to identify the role of the EP2 and EP4 receptor subtype(s) on two human colonic epithelial cell lines (Caco-2 and T84), in regulating PGE2-induced IL-8 production. Experimental approach: To identify the causative receptor, we knocked-down and over-expressed EP2 and EP4 receptor subtypes in colonic epithelial cells and studied the effect of several selective EP2/EP4 receptor agonists and antagonists. The inductions of IL-8 and EP receptor mRNA and protein expression were determined by real-time PCR and western blot analysis. The affinity of PGE2 and Bmax values for the EP2 and EP4 receptor on colonic epithelial cells were determined by radioligand-binding assays with [3H]PGE2. Key results: PGE2 had the highest affinity for the EP4 receptor subtype and promoted a robust stimulation of cAMP-dependent IL-8 synthesis. This effect was mimicked by a selective EP4 receptor agonist, ONO-AE1-329, and abolished by silencing the EP4 receptor gene by using siRNA techniques, a selective EP4 receptor antagonist (ONO-AE3-208) and a selective inhibitor (Rp-cAMP) of cAMP-dependent protein kinase. Conclusions and implications: These findings suggest that initiation and progression of colonic inflammation induced by IL-8 could be mediated, at least in part, by PGE2 acting via the EP4 receptor subtype. British Journal of Pharmacology (2009) 10.1111/j.1476-5381.2008.00056.x Mandarin translation of abstractKeywords
This publication has 33 references indexed in Scilit:
- Guide to Receptors and Channels (GRAC), 3rd editionBritish Journal of Pharmacology, 2008
- The Prevention of Colitis by E Prostanoid Receptor 4 Agonist through Enhancement of Epithelium Survival and RegenerationThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Prostaglandin E2receptor distribution and function in the gastrointestinal tractBritish Journal of Pharmacology, 2006
- Increased EP4 Receptor Expression in Colorectal Cancer Progression Promotes Cell Growth and Anchorage IndependenceCancer Research, 2006
- Prostanoid receptor expression by human airway smooth muscle cells and regulation of the secretion of granulocyte colony-stimulating factorAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2005
- Mechanisms of gene silencing by double-stranded RNANature, 2004
- Identification in human airways smooth muscle cells of the prostanoid receptor and signalling pathway through which PGE2 inhibits the release of GM‐CSFBritish Journal of Pharmacology, 2004
- Pharmacological characterization of [3H]‐prostaglandin E2 binding to the cloned human EP4 prostanoid receptorBritish Journal of Pharmacology, 2000
- CYCLOOXYGENASES 1 AND 2Annual Review of Pharmacology and Toxicology, 1998
- Jejunal release of prostaglandin E2 in Crohn's disease: Relation to disease activity and first‐degree relativesJournal of Gastroenterology and Hepatology, 1994